Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLBS1033 for ABI Improvement in Diabetic PAD
NCT02145988Phase 3Terminated
- Sponsor
- Dexa Medica
- Start
- Jun 2015
- Primary completion
- Jun 2018
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Peripheral Arterial Disease (PAD) comparing DLBS1033 with Placebo (2 arms). Primary endpoint: Resting Ankle-Brachial Index at Week 12. Started Jun 2015; status: terminated.
02
Drugs
DLBS1033
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02145988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145988.